7. Tables - UK Kidney Association

Home

Hyperkalaemia

7. Tables

Table 1: Risk factors with odds ratio of developing hyperkalaemia in community studies.
Table 2: Prevalence and outcome of hyperkalaemia in patients with eGFR > 60 ml/min in community studies.
Table 3: Prevalence of hyperkalaemia and mortality rate in patients with CKD.
Table 4: NICE CKD Guideline (2021) – Minimum number of monitoring visits per year.
Table 5: Interval for repeat blood monitoring following an episode of hyperkalaemia.
Table 6: Drugs that pose an additive effect on risk of hyperkalaemia in patients receiving RAASi and MRAs.
Table 7: Studies of efficacy of Patiromer in the treatment of hyperkalaemia.
Table 8: Studies of the efficacy of SZC in treatment of hyperkalaemia.
Table 9: Drugs implicated in development of hyperkalaemia and exacerbating factors.
Table 10: Factors associated with an increased risk of hyperkalaemia.
Table 11: Mechanism of action of drugs used in treatment of acute hyperkalaemia.
Table 12: Calcium content of IV calcium salts used in treatment of hyperkalaemia.
Table 13: Incidence of ECG changes in patients with hyperkalaemia.
Table 14: Calcium Gluconate dosing regimen for management of hyperkalaemia and other medical emergencies.
Table 15: Efficacy and risk of hypoglycaemia with conventional regimen – 10 units insulin with 25g glucose (studies without efficacy or hypoglycaemia data excluded).
Table 16: Comparison of studies performed using 5 versus 10 units insulin.
Table 17: Comparison of studies performed using weight based insulin regimen.
Table 18: Studies using 50% glucose in treatment of hyperkalaemia.
Table 19: Incidence of hypoglycaemia and correlation with pre treatment blood glucose following treatment with Insulin Glucose for hyperkalaemia.
Table 20: Risk of iatrogenic hypoglycaemia after treatment for hyperkalaemia based on the pre treatment blood glucose level.
Table 21: Risk factors for hypoglycaemia following treatment with Insulin Glucose.
Table 22: UKKA Protocol for Insulin Glucose in treatment of acute hyperkalaemia.
Table 23: Efficacy of Nebulised Salbutamol.
Table 24: Studies investigating efficacy of nebulised salbutamol in hyperkalaemia.
Table 25: Proportion of patients taking SZC 10g three times daily achieving restoration of normokalaemia (K⁺ 3.5–5.0 mmol/L) during acute phase.
Table 26: Potassium lowering effect after a single dose of oral binder. Adapted from Joyce et al, J Pharm Prac 2023.
Table 27: Timing of blood monitoring in patients with acute hyperkalaemia.
Table 28: Time to development of hypoglycaemia after Insulin Glucose treatment.
Table 29: Factors associated with an increased risk of hyperkalaemia in HD patients.
Table 30: Dialysate K⁺ prescription in chronic HD patients.
Table 31: Minimum standards for safe patient transfer.
Table 32: Drugs commonly associated with hyperkalaemia.
Table 33: Primary prevention of hyperkalaemia in non dialysis and dialysis patients.
Table 34: Secondary prevention of hyperkalaemia in non dialysis and dialysis patients.
Table 35: Incidence and outcome of cardiac arrest in out patient dialysis units.
Table 36: Timing of cardiac arrest during dialysis in out patient centres.
Table 37: Outcome of cardiac arrest in patients receiving haemodialysis (HD) in an outpatient dialysis facility versus all in hospital cardiac arrests.
Table 38: Special considerations during resuscitation in haemodialysis patients.
Table 39: Outcome of hyperkalaemic cardiac arrest with RRT during CPR.
Table 40: Summary of procedure for initiation of dialysis during CPR.